

CITATION REPORT

List of articles citing

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

DOI: [10.1093/eurheartj/ehv177](https://doi.org/10.1093/eurheartj/ehv177)

European Heart Journal, 2015, 36, 1805-11.

Source: <https://exaly.com/paper-pdf/62031571/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 343 | 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in | | 1314 |
| 342 | Heparin Kinetics: The "Holy Grail" of Periprocedural Anticoagulation for Ablation of Atrial Fibrillation. 2015 , 38, 1137-41 | | 9 |
| 341 | Arrhythmias: drugs and devices. <i>European Heart Journal</i> , 2015 , 36, 1773-5 | 9.5 | |
| 340 | Atrial fibrillation: Uninterrupted oral anticoagulation in patients undergoing catheter ablation. 2015 , 12, 381 | | |
| 339 | Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRs). 2015 , 17, 1197-214 | | 123 |
| 338 | Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. 2015 , 17, 1467-507 | | 803 |
| 337 | Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 2015 , 16, 2661-78 | | 2 |
| 336 | Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin. 2016 , 57, 342-9 | | 11 |
| 335 | Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation. 2016 , 57, 712-716 | | 4 |
| 334 | Periinterventionelle Antikoagulation bei der Vorhofflimmerablation. 2016 , 12, 233-236 | | |
| 333 | Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?. 2016 , 5, 12-3 | | 3 |
| 332 | Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression. 2016 , 27, 683-93 | | 39 |
| 331 | Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. 2016 , 68, 217-26 | | 37 |
| 330 | Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations. 2016 , 1, 157-164 | | |
| 329 | 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. 2016 , 115, 893-952 | | 76 |
| 328 | The year in cardiology 2015: arrhythmias and device therapy. <i>Egyptian Heart Journal</i> , 2016 , 68, 311-317 | 1.3 | |
| 327 | Uso de anticoagulantes directos en situaciones especiales. 2016 , 23, 89-94 | | |

| | | | |
|-----|--|-----|------|
| 326 | Rebound thrombosis within 24hours after interruption of therapy with rivaroxaban. 2016 , 212, 235-6 | | 8 |
| 325 | Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. 2016 , 2, 131-40 | | 15 |
| 324 | Atrial Fibrillation Ablation and Stroke. 2016 , 34, 307-16 | | 2 |
| 323 | New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. 2016 , 39, 739-746 | | 10 |
| 322 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 50, e1-e88 | | 589 |
| 321 | Direct oral anticoagulants: unique properties and practical approaches to management. 2016 , 102, 1620-6 | | 15 |
| 320 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962 | 9.5 | 4465 |
| 319 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 18, 1609-1678 | | 1293 |
| 318 | Rhythm control in atrial fibrillation. 2016 , 388, 829-40 | | 83 |
| 317 | Efficacy and Safety of Rivaroxaban and Warfarin in the Perioperative Period of Catheter Ablation for Atrial Fibrillation - Outcome Analysis From a Prospective Multicenter Registry Study in Japan. <i>Circulation Journal</i> , 2016 , 80, 2295-2301 | 2.9 | 24 |
| 316 | Current Optimal Anticoagulation Regimen of Rivaroxaban in Atrial Fibrillation Catheter Ablation. <i>Circulation Journal</i> , 2016 , 80, 2287-2288 | 2.9 | |
| 315 | Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation - Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging. <i>Circulation Journal</i> , 2016 , 80, 870-7 | 2.9 | 24 |
| 314 | Periprocedural Management of Novel Oral Anticoagulants During Atrial Fibrillation Ablation: Controversies and Review of the Current Evidence. 2016 , 25, 1164-1176 | | 7 |
| 313 | Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial. 2016 , 68, 1929-1940 | | 213 |
| 312 | The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. 2016 , 91, 1778-1810 | | 82 |
| 311 | Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016 , 116, S2-S12 | 7 | 6 |
| 310 | Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017 , 38, 2137-2149 | 9.5 | 162 |
| 309 | A Review of the Key Clinical Trials of 2015: Results and Implications. 2016 , 5, 109-132 | | 5 |

| | | | |
|-----|---|-----|-----|
| 308 | Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study. 2016 , 27, 549-54 | | 59 |
| 307 | Current status of catheter ablation of atrial fibrillation in Japan: Summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). 2016 , 68, 83-8 | | 15 |
| 306 | Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. 2016 , 13, 1197-202 | | 37 |
| 305 | Emerging Tools for Stroke Prevention in Atrial Fibrillation. 2016 , 4, 26-39 | | 9 |
| 304 | Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. 2016 , 18, 1787-1794 | | 18 |
| 303 | Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation. 2016 , 46, 213-24 | | 3 |
| 302 | Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859 | 9.5 | 50 |
| 301 | The year in cardiology 2015: arrhythmias and device therapy. <i>European Heart Journal</i> , 2016 , 37, 587-93 | 9.5 | |
| 300 | Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. 2016 , 117, 926-34 | | 50 |
| 299 | Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?. 2016 , 41, 279-84 | | |
| 298 | Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients. 2016 , 203, 906-8 | | 3 |
| 297 | Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. 2016 , 32, 814-23 | | 20 |
| 296 | Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. 2016 , 202, 578-85 | | 28 |
| 295 | Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. 2017 , 70, 50.e1-50.e84 | | 6 |
| 294 | 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. 2017 , 69, 871-898 | | 234 |
| 293 | Determinants of Heparin Dosing and Complications in Patients Undergoing Left Atrial Ablation on Uninterrupted Rivaroxaban. 2017 , 40, 183-190 | | 6 |
| 292 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2017 , 14, e275-e444 | | 878 |
| 291 | Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. 2017 , 120, 404-407 | | 10 |

| | | | |
|-----|--|-----|-----|
| 290 | Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives. 2017 , 16, 769-777 | | 7 |
| 289 | Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants. 2017 , 32, 1227-1235 | | 6 |
| 288 | Trends in Transesophageal Echocardiography Use, Findings, and Clinical Outcomes in the Era of Minimally Interrupted Anticoagulation for Atrial Fibrillation Ablation. 2017 , 3, 329-336 | | 14 |
| 287 | Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation. 2017 , 103, 1129-1137 | | 6 |
| 286 | Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern. 2017 , 11, 193-204 | | 11 |
| 285 | Perioperative management of patients on direct oral anticoagulants. 2017 , 15, 14 | | 65 |
| 284 | Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 2017 , 19, 132-138 | | 24 |
| 283 | Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. 2017 , 376, 1627-1636 | | 264 |
| 282 | Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin. 2017 , 48, 167-175 | | 17 |
| 281 | WITHDRAWN: 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017 , | 1.5 | |
| 280 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Journal of Arrhythmia</i> , 2017 , 33, 369-409 | 1.5 | 148 |
| 279 | Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon. 2017 , 40, 1095-1099 | | 7 |
| 278 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. 2017 , 50, 1-55 | | 58 |
| 277 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. 2017 , 14, e445-e494 | | 72 |
| 276 | Population-Based Evaluation of Major Adverse Events After Catheter Ablation for Atrial Fibrillation. 2017 , 3, 1425-1433 | | 11 |
| 275 | 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017 , 33, 345-367 | 1.5 | 93 |
| 274 | Evaluation of left atrial thrombus prior to catheter ablation of atrial fibrillation: Is it time for an individualized approach?. 2017 , 28, 1137-1139 | | 1 |
| 273 | Periprocedural Anticoagulation for Catheter Ablation of Atrial Fibrillation: Practical Implications for Perioperative Management. 2017 , 31, 1519-1526 | | 3 |

| | | |
|-----|---|----|
| 272 | Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. 2017 , 377, 495-6 | 10 |
| 271 | Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. 2017 , 12, 923-934 | 4 |
| 270 | Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation. 2017 , 193, 8-15 | 14 |
| 269 | Meta-Analysis of Safety and Efficacy of Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation. 2017 , 120, 1830-1836 ¹⁰ | 10 |
| 268 | [Procedures on patients receiving NOACs : What's possible?]. 2017 , 112, 117-124 | 1 |
| 267 | How safe are NOACs compared with phenprocoumon after pulmonary vein isolation with the cryoballoon technique using purse-string suture closure?. 2017 , 248, 201-207 | 2 |
| 266 | First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. 2017 , 244, 192-195 | 17 |
| 265 | Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban. 2017 , 17, 171 | 3 |
| 264 | Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. 2017 , 14, 19-24 | 69 |
| 263 | Recent advances in rhythm control for atrial fibrillation. 2017 , 6, 1796 | 8 |
| 262 | Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. 2018 , 72, 105-112 | 35 |
| 261 | Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. 2018 , 34, 1945-1957 | 2 |
| 260 | Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. 2018 , 29, 835-843 | 8 |
| 259 | Antithrombotic Therapy for Patients with Atrial Fibrillation. 2018 , 217-238 | |
| 258 | What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review. 2018 , 153, 577-585 | 21 |
| 257 | Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. 2018 , 41, 440-449 | 11 |
| 256 | Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. 2018 , 262, 51-56 | 17 |
| 255 | Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. 2018 , 28, 469-480 | 0 |

| | | | |
|-----|--|-----|-----|
| 254 | Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. 2018 , 26, 245-254 | | 1 |
| 253 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2018 , 20, e1-e160 | | 461 |
| 252 | Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions. 2018 , 20, 3 | | 6 |
| 251 | [S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation]. 2018 , 130, 1-8 | | |
| 250 | Selección de lo mejor del año 2017 en ablación con catéter. 2018 , 71, 303-304 | | |
| 249 | Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 2018 , 60, 514-523 | | 7 |
| 248 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. 2018 , 20, 157-208 | | 227 |
| 247 | A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial. 2018 , 4, 580-588 | | 38 |
| 246 | The year in cardiology 2017: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2018 , 39, 434-441 | 9.5 | 3 |
| 245 | Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. 2018 , 18, 71 | | 7 |
| 244 | Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients. 2018 , 41, 646-651 | | 4 |
| 243 | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE-CIRCUIT trial. <i>Journal of Arrhythmia</i> , 2018 , 34, 148-157 | 1.5 | 3 |
| 242 | Selection of the Best of 2017 in Implantable Defibrillators. 2018 , 71, 304-305 | | |
| 241 | Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. 2018 , 50, 288-302 | | 10 |
| 240 | Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. 2018 , 60, 600-606 | | 14 |
| 239 | Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018 , 39, 2942-2955 | 9.5 | 121 |
| 238 | Non-vitamin K antagonist use in the cryoballoon technique using a purse-string suture closure. 2018 , 259, 103-104 | | |
| 237 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. 2018 , 20, 1231-1242 | | 148 |

| | | |
|-----|---|-------|
| 236 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-1393 | 1094 |
| 235 | Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. 2018 , 20, e87-e95 | 11 |
| 234 | Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration. 2018 , 15, 348-354 | 8 |
| 233 | Catheter Ablation. 2018 , 1194-1210 | |
| 232 | An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. 2018 , 15, 107-115 | 42 |
| 231 | Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures. 2018 , 121, 445-449 | 14 |
| 230 | Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. 2018 , 14, 89-99 | |
| 229 | Assessment and Management of the Left Atrial Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation. 2018 , 34, 252-261 | 31 |
| 228 | Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations. 2018 , 43, 2-10 | 5 |
| 227 | 2018 Korean Guideline of Atrial Fibrillation Management. 2018 , 48, 1033-1080 | 68 |
| 226 | Is Transesophageal Echocardiography Necessary in Every Case of Atrial Fibrillation Ablation?. <i>Circulation Journal</i> , 2018 , 82, 2701-2702 | 2.9 |
| 225 | Use of oral anticoagulants in complex clinical situations with atrial fibrillation. 2018 , 150 Suppl 1, 8-24 | 2 |
| 224 | [How to manage anticoagulation in atrial fibrillation ablation]. 2018 , 67, 370-373 | |
| 223 | RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures. 2018 , 114, e89-e90 | |
| 222 | 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. 2018 , 34, 1371-1392 | 144 |
| 221 | Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and Warfarin (ASCERTAIN). 2018 , 4, 1598-1609 | 13 |
| 220 | Anticoagulation and the risk of complications in ventricular tachycardia and premature ventricular complex ablation. 2018 , 41, 1454-1460 | 2 |
| 219 | Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation. <i>Journal of Arrhythmia</i> , 2018 , 34, 428-434 | 1.5 3 |

| | | | |
|-----|--|------|-----|
| 218 | Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. <i>Circulation</i> , 2018 , 138, 627-633 | 16.7 | 14 |
| 217 | Safety and Efficacy of Uninterrupted Direct Oral Anticoagulant Administration in Elderly Patients Undergoing Catheter Ablation of Atrial Fibrillation. 2018 , 4, 601-603 | | 1 |
| 216 | Periablation Anticoagulation: Translating Research Into Clinical Practice. 2018 , 4, 589-591 | | |
| 215 | Uninterrupted Direct Oral Anticoagulant and Warfarin Administration in Elderly Patients Undergoing Catheter Ablation for Atrial Fibrillation: A Comparison With Younger Patients. 2018 , 4, 592-600 | | 8 |
| 214 | Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?. <i>European Heart Journal</i> , 2018 , 39, 2956-2958 | 9.5 | 2 |
| 213 | Selection of the Best of 2017 in Catheter Ablation. 2018 , 71, 303-304 | | |
| 212 | Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: A safe approach. 2018 , 41, 1001 | | 6 |
| 211 | Effects and Risks of Heparin Bridging and Different Modes of Interruption/Resumption of Rivaroxaban on Perioperative Complications of Catheter Ablation for Atrial Fibrillation - Another Analysis of the JACRE-R Registry. <i>Circulation Journal</i> , 2018 , 82, 346-352 | 2.9 | 5 |
| 210 | Atrial fibrillation in athletes: From epidemiology to treatment in the novel oral anticoagulants era. 2018 , 72, 269-276 | | 7 |
| 209 | Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. 2018 , 36, e12457 | | 7 |
| 208 | Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. 2018 , 20, 1612-1620 | | 17 |
| 207 | National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. 2018 , 27, 1209-1266 | | 122 |
| 206 | Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation. 2018 , 53, 341-346 | | 5 |
| 205 | Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation. 2018 , 26, 352-360 | | 0 |
| 204 | Manejo perioperatorio del paciente anticoagulado con fibrilaci3n auricular no valvular. 2018 , | | 0 |
| 203 | Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. 2018 , 154, 1121-1201 | | 502 |
| 202 | Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism. 2018 , 16, 501-514 | | 2 |
| 201 | A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. 2018 , 270, 167-171 | | 16 |

| | | |
|-----|--|-------------------|
| 200 | Uninterrupted NOAC therapy in patients undergoing catheter ablation of atrial fibrillation: "Dual anticoagulant therapy" ready for primetime or systematic overtreatment?. 2018 , 270, 185-186 | 2 |
| 199 | Perioperative Safety and Efficacy of Different Anticoagulation Strategies With Direct Oral Anticoagulants in Pulmonary Vein Isolation: A Meta-Analysis. 2018 , 4, 794-806 | 10 |
| 198 | Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?. 2019 , 21, 181-183 | 3 |
| 197 | Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation. 2019 , 20, 147-152 | 1 |
| 196 | Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. 2019 , 21, 259-267 | 34 |
| 195 | Thromboembolic Events Following Atrial Fibrillation Cardioversion and Ablation: What's the Culprit?. 2019 , 55, | |
| 194 | Atrial Fibrillation Ablation: Indications and Techniques. 2019 , 21, 43 | 1 |
| 193 | Prothrombotic Responses After Catheter Ablation for Atrial Fibrillation During Uninterrupted Oral Anticoagulant Agent Administration. 2019 , 5, 1418-1427 | 4 |
| 192 | How minimally interrupted direct oral anticoagulants affect intraprocedural anticoagulation during atrial fibrillation ablation? Insights from a Japanese single-center retrospective study. <i>Journal of Arrhythmia</i> , 2019 , 35, 716-724 | 1.5 |
| 191 | Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation. 2019 , 5, 1396-1405 | 13 |
| 190 | Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide. 2019 , 23, 352-368 | 3 |
| 189 | Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography. 2019 , 1, 231-237 | 2 |
| 188 | Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study. <i>Circulation Journal</i> , 2019 , 83, 2017-2024 | 11 ^{2,9} |
| 187 | Application-based management of perioperative anticoagulant therapy: description of POPACTApp. 2019 , 404, 633-645 | 1 |
| 186 | Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report. 2019 , 20, 27-29 | 0 |
| 185 | Continuous anticoagulation with catheter ablation: answers and questions. <i>European Heart Journal</i> , 2019 , 40, 3022-3025 | 9.5 0 |
| 184 | Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. 2019 , 21, 879-885 | 5 |
| 183 | Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial. 2019 , 2, e191994 | 29 |

| | | | |
|-----|---|-----|-----|
| 182 | Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019 , 40, 3013-3021 | 9.5 | 75 |
| 181 | Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. 2019 , 9, 6690 | | 10 |
| 180 | Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. 2019 , 53, 48-54 | | 5 |
| 179 | Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. 2019 , 34, 1533-1541 | | 8 |
| 178 | Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. 2019 , 94, 697-709 | | 123 |
| 177 | Silent cerebral lesions and cognitive function after pulmonary vein isolation with an irrigated gold-tip catheter: REDUCE-TE Pilot study. 2019 , 30, 877-885 | | 5 |
| 176 | Pulmonary Vein Isolation for Atrial Fibrillation. 2019 , 222-234.e4 | | |
| 175 | To Maintain or Cease Non-Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations. 2019 , 45, 171-179 | | 10 |
| 174 | Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation. 2019 , 60, 1315-1320 | | 9 |
| 173 | Atrial fibrillation catheter ablation: an updated review of current guidelines and expert consensus documents. 2019 , 30, 371-376 | | 4 |
| 172 | The Coagulation and Atrial Fibrillation Ablation Cascades: A Complex Interaction. 2019 , 5, 1428-1431 | | 2 |
| 171 | Complications of catheter ablation: incidence, diagnosis and clinical management. 2019 , 30, 363-370 | | 1 |
| 170 | Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs. 2019 , 183, 119-123 | | 7 |
| 169 | The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38 | 7 | 19 |
| 168 | When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. <i>European Heart Journal</i> , 2019 , 40, 1531-1537 | 9.5 | 19 |
| 167 | The year in cardiology 2018: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2019 , 40, 803-808 | 9.5 | 1 |
| 166 | Catheter Ablation for Atrial Fibrillation. 2019 , 15, 19-25.e1 | | 1 |
| 165 | Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials. 2019 , 42, 198-205 | | 5 |

| | | | |
|-----|--|-----|---|
| 164 | Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants. 2019 , 21, 48-53 | 9 | |
| 163 | Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. 2019 , 21, 590-597 | 17 | |
| 162 | Insight into the perioperative management of direct oral anticoagulants: concerns and considerations. 2019 , 20, 465-472 | 2 | |
| 161 | Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. 2019 , 39, 94-108 | 1 | |
| 160 | To continue or minimally interrupt direct oral anticoagulants around ablation for atrial fibrillation: that is the question. 2019 , 21, 531-532 | 1 | |
| 159 | Feasibility and safety of uninterrupted apixaban in patients undergoing radiofrequency ablation for atrial fibrillation. 2020 , 58, 35-41 | 3 | |
| 158 | Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. 2020 , 18, 792-799.e61 | 27 | |
| 157 | Higher initial weight-based heparin dosing is required with direct oral anticoagulants during catheter ablation for atrial fibrillation. 2020 , 58, 185-191 | 5 | |
| 156 | HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: A subanalysis of the Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registries. 2020 , 75, 82-89 | 6 | |
| 155 | Prospective comparison of periprocedural coagulation markers among uninterrupted anticoagulants for atrial fibrillation ablation. 2020 , 17, 391-397 | 1 | |
| 154 | Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management. 2020 , 43, 14-23 | 6 | |
| 153 | Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants. 2020 , 58, 141-146 | 0 | |
| 152 | Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis. 2020 , 50, 201-210 | 2 | |
| 151 | Stroke and thromboembolism prevention in atrial fibrillation. 2020 , 106, 10-17 | 23 | |
| 150 | Atrial fibrillation ablation in adults with congenital heart disease on uninterrupted oral anticoagulation is safe and efficient. 2020 , 109, 904-910 | 2 | |
| 149 | Uninterrupted Dabigatran Administration Provides Greater Inhibition against Intracardiac Activation of Hemostasis as Compared to Vitamin K Antagonists during Cryoballoon Catheter Ablation of Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 1 |
| 148 | Catheter ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six randomized controlled trials. 2020 , 21, 483-490 | 5 | |
| 147 | Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures. 2020 , 22, 132-137 | 1 | |

| | | | |
|-----|---|-----|----|
| 146 | Is transesophageal echocardiography necessary in patients undergoing ablation of atrial fibrillation on an uninterrupted direct oral anticoagulant regimen? Results from a prospective multicenter registry. 2020 , 17, 2093-2099 | | 13 |
| 145 | Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri-procedural period of catheter ablation for atrial fibrillation. <i>Journal of Arrhythmia</i> , 2020 , 36, 634-641 | 1.5 | 3 |
| 144 | Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. <i>Journal of Arrhythmia</i> , 2020 , 36, 644-651 | 1.5 | 1 |
| 143 | Optimizing prognosis in atrial fibrillation: A call to action in Portugal. 2020 , | | |
| 142 | Cardiac Tamponade During Uninterrupted Oral Anticoagulant Therapy for Catheter Ablation for Atrial Fibrillation. 2020 , 6, 796-798 | | 1 |
| 141 | Ablation of Atrial Fibrillation Without Left Atrial Appendage Imaging in Patients Treated With Direct Oral Anticoagulants. 2020 , 13, e008301 | | 4 |
| 140 | Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis. 2020 , 43, 1104-1114 | | 4 |
| 139 | The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. 2020 , 36, 1847-1948 | | 82 |
| 138 | A prospective multicenter study of direct comparison of feasibility and safety of pulmonary vein isolation using the minimally interrupted apixaban between second-generation cryoballoon and radiofrequency ablation of paroxysmal atrial fibrillation: J-HIT apixaban. <i>Journal of Arrhythmia</i> , 2020 , 36, 617-623 | 1.5 | |
| 137 | One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. 2020 , 145, 676-681 | | 1 |
| 136 | Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs. 2021 , 61, 551-557 | | 1 |
| 135 | Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?. 2020 , 22, O28-O41 | | |
| 134 | Periprocedural Anticoagulation Interruption Strategies for Ablation of Atrial Fibrillation: What Is the Best Current Practice?. 2020 , 145, 682-684 | | |
| 133 | Clinical efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in patients aged 80 years. 2020 , 43, 814-821 | | 1 |
| 132 | Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: Comparisons across four drugs and two dose regimens. 2020 , 31, 1996-2004 | | 2 |
| 131 | Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation. 2020 , 6, 609-619 | | 26 |
| 130 | Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation. 2020 , 58, 381-399 | | |
| 129 | Thrombus in the left atrial appendage in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants in clinical practice-A multicenter registry. 2020 , 31, 2005-2012 | | 1 |

| | | | |
|-----|--|-----|----|
| 128 | Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. 2020 , 1 | | 1 |
| 127 | Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study. 2020 , 7, 197 | | |
| 126 | Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation. <i>Journal of Arrhythmia</i> , 2020 , 36, 417-424 | 1.5 | 3 |
| 125 | Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation. 2020 , 31, 2626-2631 | | 4 |
| 124 | Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies. 2020 , 34, 209-214 | | 3 |
| 123 | Limited efficacy of a figure-of-eight suture for hemostasis after cryoballoon atrial fibrillation ablation with uninterrupted oral anticoagulants. 2020 , 76, 30-34 | | 3 |
| 122 | Intracardiac Fibrinolysis and Endothelium Activation Related to Atrial Fibrillation Ablation with Different Techniques. 2020 , 2020, 1570483 | | 3 |
| 121 | Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter?. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 13 |
| 120 | [Perioperative management of anticoagulation among patients with atrial fibrillation]. 2020 , 162, 44-47 | | |
| 119 | Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. 2020 , 34, 371-381 | | 7 |
| 118 | Periprocedural Management of Cardiac Tamponade During Catheter Ablation for AF Under Uninterrupted DOAC and Warfarin. 2020 , 6, 786-795 | | 4 |
| 117 | Clinical experience of uninterrupted oral anticoagulants during atrial fibrillation ablation in elderly patients: a comparison with non-elderly patients. 2020 , 35, 1454-1462 | | 1 |
| 116 | Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis. 2020 , 7, 107 | | 8 |
| 115 | Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants. 2021 , 60, 147-154 | | 3 |
| 114 | Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. 2021 , 60, 407-417 | | 2 |
| 113 | Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. 2021 , 76, 288-295 | | 3 |
| 112 | Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. 2021 , 110, 759-774 | | 3 |
| 111 | Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. 2021 , 23, 65-72 | | |

| | | | |
|-----|--|-----|------|
| 110 | Safety of catheter ablation of atrial fibrillation without pre- or peri-procedural imaging for the detection of left atrial thrombus in the era of uninterrupted anticoagulation. <i>Journal of Arrhythmia</i> , 2021 , 37, 28-32 | 1.5 | 0 |
| 109 | 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. <i>European Heart Journal</i> 2021 , 42, 373-408 | 9.5 | 1676 |
| 108 | Direct Oral Anticoagulants and Atrial Fibrillation Ablation. 2021 , 225-234 | | |
| 107 | Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials. 2021 , 34, 651-659 | | 0 |
| 106 | Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation. 2021 , 23, 1961-1969 | | 0 |
| 105 | AF Radiofrequency Ablation Using CARTO 3D System. 2021 , 189-192 | | |
| 104 | Protocol driven periprocedural anticoagulation for left atrial ablation. 2021 , 32, 639-646 | | |
| 103 | Comprehensive Intraprocedural Unfractionated Heparin Protocol During Catheter Ablation of Atrial Fibrillation in the Presence of Direct Oral Anticoagulants and Wide Spectrum of Body Mass Index. 2021 , 26, 349-358 | | 1 |
| 102 | Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art. 2021 , 46, 100622 | | 1 |
| 101 | Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. 2021 , 21, 214 | | 1 |
| 100 | Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials. 2021 , 1-7 | | 1 |
| 99 | Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta-analysis. 2021 , 32, 1995-2004 | | 0 |
| 98 | Atrial Fibrillation and Ischemic Stroke: A Clinical Review. 2021 , 41, 348-364 | | 4 |
| 97 | Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. 2021 , 41, 365-387 | | 0 |
| 96 | 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. 2021 , 23, 1612-1676 | | 99 |
| 95 | Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). 2021 , 74, 437.e1-437.e116 | | 3 |
| 94 | Arrhythmia Recurrence After Atrial Fibrillation Ablation: Impact of Warfarin vs. Non-Vitamin K Antagonist Oral Anticoagulants. 2021 , 1 | | |
| 93 | JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. <i>Circulation Journal</i> , 2021 , 85, 1104-1244 | 2.9 | 17 |

| | | | |
|----|--|-----|----|
| 92 | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 1 |
| 91 | Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials. 2021 , 77, 652-659 | | 3 |
| 90 | JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. <i>Journal of Arrhythmia</i> , 2021 , 37, 709-870 | 1.5 | 22 |
| 89 | Thrombus or No Thrombus: Is That the Embolic Question?. 2021 , 77, 2887-2889 | | |
| 88 | Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. 2021 , 203, 27-32 | | 2 |
| 87 | Comparison of uninterrupted direct oral anticoagulation with vitamin-K antagonists during AF-ablation in the clinical routine. A single center register. 2021 , 44, 1243-1248 | | 1 |
| 86 | Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. 2021 , 44, 1177-1182 | | 4 |
| 85 | A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (Real-AF): design and objectives. 2021 , 62, 487-494 | | 1 |
| 84 | Use of NOACs Versus Vitamin K Antagonist in Atrial Fibrillation Catheter Ablation: An Updated Meta-analysis With Subgroup Analysis. 2021 , | | |
| 83 | Optimizing prognosis in atrial fibrillation: A call to action in Portugal. 2021 , 40, 595-605 | | |
| 82 | Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study. 2021 , 19, 53 | | |
| 81 | 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. 2021 , 26, 4594 | | 31 |
| 80 | Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. 2021 , 91, 75-80 | | |
| 79 | Uninterrupted Direct Oral Anticoagulants Without a Change in Regimen for Catheter Ablation for Atrial Fibrillation Is an Acceptable Protocol. 2021 , 3, 481-487 | | |
| 78 | Running after Activated Clotting Time Values in Patients Receiving Direct Oral Anticoagulants: A Potentially Dangerous Race. Results from a Prospective Study in Atrial Fibrillation Catheter Ablation Procedures. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 3 |
| 77 | Anticoagulant therapy in catheter ablation of atrial fibrillation and flutter. 2021 , 20, 2974 | | |
| 76 | New Insights on Uninterrupted Anticoagulation in Left Atrial Catheter Ablation Procedures. <i>Circulation Journal</i> , 2021 , | 2.9 | |
| 75 | Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have Enough Evidence to Solve the Dilemma?). 2021 , 35, 1191-1204 | | |

| | | | |
|----|--|-----|----|
| 74 | Atrial fibrillation. 2022 , 223-251.e1 | | |
| 73 | Atrial Fibrillation Ablation. 2022 , 44-49 | | |
| 72 | Outcomes of uninterrupted vs interrupted Periprocedural direct oral Anticoagulants in atrial Fibrillation ablation: A meta-analysis. <i>Journal of Arrhythmia</i> , 2021 , 37, 384-393 | 1.5 | 1 |
| 71 | [Recommendations on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (Based on 2018 European Heart Rhythm Association Practical Guide)]. <i>Kardiologiya</i> , 2019 , 59, 68-79 | 1.5 | 1 |
| 70 | 2018 Korean Guidelines for Catheter Ablation of Atrial Fibrillation: Part II. 2018 , 19, 235-284 | | 1 |
| 69 | Antithrombotic Treatment after Atrial Fibrillation Ablation. 2020 , 26, 2703-2714 | | 0 |
| 68 | Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation. 2016 , 12, 330-335 | | 0 |
| 67 | Safety of Catheter Ablation of Atrial Fibrillation Under Uninterrupted Rivaroxaban Use. <i>Arquivos Brasileiros De Cardiologia</i> , 2020 , 114, 435-442 | 1.2 | 1 |
| 66 | 2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. <i>Korean Journal of Medicine</i> , 2018 , 93, 110-132 | 0.5 | 6 |
| 65 | The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management. <i>Korean Journal of Medicine</i> , 2019 , 94, 40-56 | 0.5 | 4 |
| 64 | A Patient With Asymptomatic Cerebral Lesions During AF Ablation: How Much Should We Worry?. <i>Journal of Atrial Fibrillation</i> , 2016 , 8, 1323 | 0.8 | 10 |
| 63 | Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological Procedures. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2083 | 0.8 | 2 |
| 62 | Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. 2019 , 67, 1200-1212 | | 3 |
| 61 | Anticoagulation in Atrial Fibrillation Patients. | | 1 |
| 60 | Recent advances in management of anti-coagulation in atrial fibrillation. 2015 , 2, 1-5 | | |
| 59 | Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.. 2017 , 18, 148-150 | | |
| 58 | Additional Comments 2: Periprocedural Anticoagulation Therapy of Atrial Fibrillation Ablation. 2017 , 106, 1871-1874 | | |
| 57 | Atrial Fibrillation Catheter Ablation: Overcoming Complications and Improving Success. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017 , 8, 2874-2885 | 1.1 | 0 |

| | | | |
|----|--|-----|---|
| 56 | Left Atrium and Left Atrial Appendage Screening Prior to Atrial Fibrillation Ablation: A Comprehensive Review of the Literature. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018 , 9, 3163-3171 | 1.1 | |
| 55 | Direct anticoagulants and their new indications. 2018 , 20, 85-88 | | |
| 54 | Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018 , 9, 3274-3281 | 1.1 | |
| 53 | Edoxaban - its properties and role in antithrombotic prophylaxis in atrial fibrillation. 2018 , 17, 169-172 | | |
| 52 | Direct Acting Oral Anticoagulants in electrotherapy. 2018 , 3, 12-16 | | |
| 51 | Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. 2019 , 5, 24 | | |
| 50 | Novel Oral Anticoagulants [Do Real-world Data Support our Expectations?]. 2019 , 5, 48 | | |
| 49 | Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation. 2019 , 68-77 | | |
| 48 | ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION. 2019 , 62-71 | | |
| 47 | The periprocedural management of oral anticoagulation in atrial fibrillation ablation: is it really clear which is the best approach?. 2020 , 21, 491-493 | | |
| 46 | Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE. <i>Journal of Arrhythmia</i> , 2021 , 37, 70-78 | 1.5 | 0 |
| 45 | Catheter ablation and anticoagulation therapy. 2020 , 31, 577-583 | | |
| 44 | Prospective Randomized Study of the Safety and Efficacy of Interrupted Anticoagulant Therapy in the Perioperative Period of Catheter Ablation for Atrial Fibrillation: The SEACOAST Rhythm AF Trial. 2020 , 32, 221-232 | | |
| 43 | Uninterrupted Direct Oral Anticoagulants in Atrial Fibrillation Catheter Ablation: Ready for Prime Time. <i>Arquivos Brasileiros De Cardiologia</i> , 2020 , 114, 443-445 | 1.2 | 1 |
| 42 | [Prevention of thromboembolic complications during cardioversion and catheter ablation in patients with atrial fibrillation: review of key randomized trials]. <i>Kardiologiya</i> , 2020 , 60, 99-106 | 1.5 | |
| 41 | Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation. <i>Indian Pacing and Electrophysiology Journal</i> , 2020 , 20, 261-264 | 1.5 | |
| 40 | Who Needs Catheter Ablation And Which Approach?. <i>Journal of Atrial Fibrillation</i> , 2015 , 8, 1335 | 0.8 | 1 |
| 39 | Radiofrequency Catheter Ablation: How to Manage and Prevent Collateral Damage?. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020 , 11, 4234-4240 | 1.1 | |

| | | | |
|----|--|------|----|
| 38 | Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation.. <i>Journal of Arrhythmia</i> , 2022 , 38, 58-66 | 1.5 | 1 |
| 37 | 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021 , 37, 1389-1426 | 1.5 | 8 |
| 36 | 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2021 , 122, | 7 | 16 |
| 35 | Different Kinetics of Activated Clotting Time among Uninterrupted Oral Anticoagulants during Catheter Ablation Procedure.. <i>Journal of Clinical Pharmacology</i> , 2021 , | 2.9 | |
| 34 | JCS/JHRS 2021 Guideline Focused Update on Non-Pharmacotherapy of Cardiac Arrhythmias.. <i>Circulation Journal</i> , 2022 , | 2.9 | 1 |
| 33 | Radiofrequency Catheter Ablation: How to Manage and Prevent Collateral Damage?. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020 , 11, :4234-4240 | 1.1 | 1 |
| 32 | Antithrombotic Management of Atrial Fibrillation Patients Presenting with Coronary Artery Disease: A Consensus Document of the Chinese Society of Cardiology. <i>Cardiology Discovery</i> , 2021 , 1, 15-28 | | |
| 31 | UBLED AF (Uninterrupted BBlackpool EDOxaban vs Warfarin vs Rivaroxaban in Atrial Fibrillation/Flutter ablation) Study.. <i>Journal of Atrial Fibrillation</i> , 2021 , 14, 20200445 | 0.8 | 1 |
| 30 | Rationale and study design of the Italian Registry in the setting of atrial fibrillation ablation with Rivaroxaban - IRIS.. <i>Minerva Cardiology and Angiology</i> , 2022 , | 2.4 | |
| 29 | JCS/JHRS 2021 guideline focused update on non-pharmacotherapy of cardiac arrhythmias.. <i>Journal of Arrhythmia</i> , 2022 , 38, 1-30 | 1.5 | 1 |
| 28 | Atrial Fibrillation. 2022 , 294-318 | | |
| 27 | MRI-Detected Brain Lesions and Cognitive Function in Atrial Fibrillation Patients Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.. <i>Circulation</i> , 2022 , | 16.7 | 1 |
| 26 | 2021 Korean Heart Rhythm Society Guidelines for Catheter or Surgical Ablation of Atrial Fibrillation. <i>Korean Journal of Medicine</i> , 2022 , 97, 5-22 | 0.5 | |
| 25 | Effectiveness and Safety of Rivaroxaban and Dabigatran in Non-Valvular Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry. <i>SSRN Electronic Journal</i> , | 1 | |
| 24 | Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention.. <i>Journal of Clinical Medicine</i> , 2022 , 11, | 5.1 | |
| 23 | JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Journal of Arrhythmia</i> , | 1.5 | |
| 22 | Optimal Anticoagulant Strategy for Periprocedural Management of Atrial Fibrillation Ablation: A Systematic Review and Network Meta-Analysis.. <i>Journal of Clinical Medicine</i> , 2022 , 11, | 5.1 | 0 |
| 21 | JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. <i>Circulation Journal</i> , 2022 , CJ-20-1212 | 12 | 6 |

| | | | |
|----|--|-----|----|
| 20 | Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!. <i>Egyptian Heart Journal</i> , 2022 , 74, 18 | 1.3 | 1 |
| 19 | Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 864899 | 5.4 | |
| 18 | The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.. <i>Vascular Pharmacology</i> , 2022 , 106994 | 5.9 | |
| 17 | Data_Sheet_1.docx. 2020 , | | |
| 16 | Antikoagulation bei linksatrialer Katheterablation. <i>Nervenheilkunde</i> , 2022 , 41, 405-410 | 0.3 | |
| 15 | Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation. 2022 , 11, 4452 | | ○ |
| 14 | Real-World Investigation on Anticoagulation Management Before and After Catheter Ablation for Atrial Fibrillation in Japan [Periprocedural and Long-Term Outcomes] 2022 , | | ○ |
| 13 | Stroke Prevention in Atrial Fibrillation. 2022 , | | |
| 12 | Benefits and Risks Associated with Long-term Oral Anticoagulation after Successful Atrial Fibrillation Catheter Ablation: Systematic Review and Meta-analysis. 2022 , 28, 107602962211184 | | ○ |
| 11 | Safety of a single bolus administration of heparin without the measurement of activated clotting time during cryoballoon ablation: a prospective randomized controlled trial. | | ○ |
| 10 | Warfarin versus non-vitamin k antagonist oral anticoagulants: how the degree of coagulation differs during catheter ablation of atrial fibrillation. 2022 , 29, 13-20 | | ○ |
| 9 | EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. 2019 , 4-85 | | 11 |
| 8 | Comparison of Interrupted and Uninterrupted Anticoagulation Therapy for Patients With Atrial Fibrillation Undergoing Catheter Ablation: A Meta-Analysis. 2022 , | | ○ |
| 7 | Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry. 2022 , 28, 107602962211233 | | ○ |
| 6 | Real-world comparison of in-hospital complications after catheter ablation for atrial fibrillation between non-antivitamin K anticoagulants and warfarin: A propensity-matched analysis using nation-wide database. 2023 , 44, 101174 | | ○ |
| 5 | Anticoagulation for Atrial Fibrillation. Publish Ahead of Print, | | ○ |
| 4 | Safety of Continuing Anticoagulation Prior to Cardiac Catheterization in Pediatric Patients: A Los Angeles Center Experience. | | ○ |
| 3 | Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2. 9 , | | ○ |

- 2 Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters. **2023**, 12, 2236 ○
- 1 One day interruption of NOAC is associated with low risk of periprocedural adverse events during pulmonary vein isolation if combined with left atrial thrombus exclusion with computed tomography. ○